Germany· DE-A57-1e6297d009812286
Normosang
A medicinal product containing human hemin, registered in Germany by Recordati Rare Diseases.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Human Hemin
- Manufacturer
- Recordati Rare Diseases
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Human hemin in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandNormosangOrphan Europe SARL
- BelgiumNormosang 25 mg/mlRecordati Rare Diseases
- IrelandNormosang 25 mg/ml, concentrate for solution for infusionRecordati Rare Diseases
- IcelandNormosangRecordati Rare Diseases
- NorwayNormosangRecordati Rare Diseases
- SwedenNormosang 25 mg/ml Koncentrat till infusionsvätska, lösningRecordati Rare Diseases
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Normosang
- Belgium · Normosang
- Czechia · Normosang
- Denmark · Normosang
- Estonia · Normosang
- Spain · Normosang
- Finland · Normosang
- France · Normosang
- United Kingdom (Northern Ireland) · Normosang
- Croatia · Normosang
- Hungary · Normosang
- Ireland · Normosang
- Iceland · Normosang
- Italy · Normosang
- Lithuania · Normosang
- Luxembourg · Normosang
- Latvia · Normosang
- Malta · Normosang
- Netherlands · Normosang
- Norway · Normosang
- Poland · Human Hemin Orphan Europe
- Portugal · Normosang
- Sweden · Normosang
- Slovenia · Normosang
- Slovakia · Normosang
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a8fdd595-7c7c-4189-ba36-a43a3ac8b3fc GET /v1/drugs/a8fdd595-7c7c-4189-ba36-a43a3ac8b3fc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Intravenous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Human Hemin",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about human hemin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.